Vivos Therapeutics(VVOS) - 2024 Q1 - Earnings Call Transcript

Conference Call Participants For the quarter ended March 31, 2024, net cash provided from financing activities of $3.6 million related to our February warrant inducement transaction. This compares to net cash provided from financing activities in the comparable 2023 period of $7.4 million, reflecting our January 2023 private placement. On the revenue front, the growth initiatives that we've announced in the past have included the following eight key items: one, targeting large and small DSO groups, DSO dent ...